ADI-PEG 20: Phase Ib started

Polaris began an open-label, dose-escalation, U.S. Phase Ib trial to evaluate intramuscular ADI-PEG 20 plus Abraxane nab-paclitaxel and gemcitabine in about 21 patients. The maximum tolerated dose (M...